InVivo gets FDA OK to test bioscaffold in acute SCI patients

04/8/2013 | RTT News

InVivo Therapeutics has received investigational device exemption approval from the FDA to evaluate the use of its biopolymer scaffold in treating patients with acute spinal cord injuries. The study will take place over 15 months, and the company hopes to submit to the FDA the details of the trial by the end of next year.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC